Why You've Stopped Losing Weight on Wegovy — and What to Do Next

The scales haven't moved in weeks. Here's what that usually means.

You've been injecting every week, keeping to your plan, and then one morning the number just stops changing. It stays there for two weeks, then three. The frustration is real. But a plateau is not the same as the medicine stopping work, and understanding the difference matters before you make any changes.

Semaglutide reduces appetite by acting on GLP-1 receptors involved in hunger signalling and gastric emptying. As your body adjusts to a given dose, the acute appetite suppression you felt early on can soften. That's biology, not failure. The NHS patient information on semaglutide explains that weight loss typically slows as treatment progresses and the body reaches a new set point, which varies considerably between individuals.

A question our prescribers hear most weeks is: "I was doing so well and now nothing is moving, does that mean it's stopped working?" The honest answer is: not necessarily. The medicine may still be holding appetite in check, preventing regain, even if the scale has paused. The distinction between active plateau and genuine treatment ineffectiveness takes clinical assessment to untangle. If you're unsure where you sit, a conversation through our FAQs page is a starting point, but a prescriber review is the real answer.

Why the dose you're on right now changes everything

Wegovy's titration schedule starts at 0.25mg and moves upward through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, with each step typically four weeks apart. If you've hit a plateau partway through that journey, the most clinically significant question is whether you're still on a lower titration dose or whether you've reached the top.

At sub-maintenance doses, the full weight-management effect hasn't yet been reached. The pattern of weight loss on Wegovy tends to be steeper once the 2.4mg dose is established. Plateauing at 0.5mg or 1.0mg is not the same clinical picture as plateauing at 2.4mg for three months. Your prescriber sets the pace of titration based on how your body is tolerating each step, which is exactly why any decision to change the schedule belongs with them, not with a self-adjusted injection.

NICE's appraisal of semaglutide for weight management notes that if less than 5% weight loss has occurred after six months at the maintenance dose, continuing treatment should be reviewed. That's a specific clinical threshold, not something to apply informally. If you're earlier in the dose journey, that threshold doesn't yet apply to you. Understanding which situation you're in is the first thing a prescriber will clarify.

The lifestyle factors that quietly pull weight loss back to zero

Wegovy reduces hunger, but it doesn't override a consistent energy surplus. As the medicine settles in, some people unconsciously eat more than they did in the early weeks (portions creep, snacking resumes) because the acute appetite suppression of a new dose has normalised. This is not weakness; it's adaptation, and it's predictable.

Three things tend to matter most during a plateau. Protein intake: semaglutide-related weight loss includes lean muscle mass as well as fat, and inadequate protein accelerates that loss while blunting the metabolic rate needed to keep losing weight. Sleep: consistently poor sleep raises ghrelin (the hunger hormone) and lowers the satiety signals that semaglutide is working to amplify, they pull in opposite directions. Resistance activity: muscle tissue burns more energy at rest than fat; preserving or building it during treatment keeps the metabolic floor higher. None of these is a cure for a plateau on its own, but together they're often where the stall is hiding.

For a detailed look at how these factors interact with treatment, the Wegovy overview page covers the lifestyle support that tends to get results. The NICE technology appraisal for semaglutide (TA875) also underlines that the medicine is intended alongside a reduced-calorie diet and increased physical activity, the two were never optional extras.

When to actually speak to a prescriber, and what that conversation looks like

There's a meaningful difference between a temporary plateau that self-resolves and one that signals something worth investigating. As a rough guide: if you're still on a titration dose and weight has paused, give the next dose step time to take effect. If you've been on 2.4mg for more than 12 weeks without meaningful movement, a clinical review is appropriate. If you've noticed the medicine's appetite effect has genuinely diminished (you're hungry in a way you weren't before) tell your prescriber directly; that's useful clinical information.

At nume, every repeat order goes through a fresh clinical review before dispatch. That's not a formality, it's the moment a prescriber looks at how treatment is actually going, and the right moment to raise a plateau. There's no extra hoop to jump through. If you've stopped losing weight on Wegovy and want to understand the clinical reasons why that happens and what can be done, that's covered more fully in its own dedicated page. The short version is: sometimes it does stall, and your prescriber can assess and act on the reasons why Wegovy weight loss has stopped, drawing on what's known about why this happens and the options available when it does. The weight loss treatment overview covers what's licensed in the UK if you're weighing up options more broadly. And if cost is part of what's making you hesitant to continue, the Wegovy cost page breaks down what private treatment actually includes. For clinical questions specific to your situation, the best step is to speak to our prescribers through a free consultation, they review every case the same day it comes in.